Methotrexate It is a slow-acting steroid-sparing agent, which could be an alternative treatment to OMP in active or unstable vitiligo
FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know On April 15, 2026, the FDA announced a significant regulatory update: injectable GHK-Cu (copper tripeptide-1) will be removed from the Category 2 bulk substances list by July 2026
Among the 60 participants treated with GSBR-1290, only one (2.8%, from the T2DM group) discontinued the study due to drug-related adverse events (AEs)
Vice versa, direct occlusion of the superior mesenteric vessels, vein, artery, or vein and artery (i.e., portal, caval hypertension, aortal hypotension, peripheral lesions) rapidly induced the intracranial (superior sagittal sinus) hypertension, brain swelling, and lesions [14,15,16]
Both tGSH ( P = 0.0055) and GSSG ( P = 0.0071) concentrations and the GSSG/GSH ratio ( P = 0.0227) correlated positively with disease duration until the first visit
What should be considered before using GHK Cu for longevity or anti-aging purposes
